Corporate Information – Page 19 – Alligator Bioscience

2020-06-23

Alligator Bioscience receives first patent approval for ATOR-1017

Lund, Sweden, June 23, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today that the United States Patent and Trademark Off ...

2020-06-15

Lund, Sweden, June 15, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced the appointment of Marie Svensson as Chief Fina ...

2020-06-10

New Preclinical Data Show That ALG.APV-527 has Potential for a Favorable Safety Profile Does Not Induce Systemic T-cell Activation at High D ...

2020-06-04

Regulatory

Lund, Sweden, June 4, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) and Scandion Oncology (Spotlight, Sweden: SCOL), today announced ...

2020-06-01

Regulatory

Lund, Sweden, June 1, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that the company received an additional USD 0.5 ...

2020-05-29

Regulatory

Lund, Sweden, May 29, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX), announces that the company today presents additional novel data ...

2020-05-05

Lund, Sweden, May 5, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX),today announces that an annual general meeting was held in the co ...

2020-04-27

Regulatory

Lund, Sweden, April 27, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX), announces that the company today presents the status of the o ...

2020-04-20

Lund, Sweden, April 20, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announced that the company's Nomination Committee, ...